Latest News

Feb 12, 2026
BioXcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for IGALMI® in the At-Home SettingVIEW RELEASE
Jan 20, 2026
BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI® Label Expansion in the At-Home SettingVIEW RELEASE
Jan 12, 2026
BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home SettingVIEW RELEASE

Stock Information

BioXcel Therapeutics, Inc.

Feb 12, 2026 03:32 PM

MARKET/SYMBOL

Nasdaq:

BTAI

PRICE

1.54

CHANGE

-0.08 (-4.93%)
Scroll to Top

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries. This web site is intended to help healthcare professionals practicing in the US find scientifically balanced, evidence-based information about Bioxcel Therapeutics drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.